How Analysts Feel About Adamas Pharmaceuticals Inc (ADMS) After Today’s Significant Increase?

September 17, 2017 - By Nellie Frank

The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is a huge mover today! The stock increased 4.82% or $0.99 on September 15, reaching $21.53. About 1.18 million shares traded. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 0.40% since September 17, 2016 and is downtrending. It has underperformed by 17.10% the S&P500.
The move comes after 7 months positive chart setup for the $484.73M company. It was reported on Sep, 17 by Barchart.com. We have $22.61 PT which if reached, will make NASDAQ:ADMS worth $24.24M more.

Wall Street await Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to release earnings on November, 2. Analysts forecast EPS of $-1.06, down exactly $0.40 or 60.61 % from 2014’s $-0.66 EPS. After posting $-0.93 EPS for the previous quarter, Adamas Pharmaceuticals Inc’s analysts now forecast 13.98 % negative EPS growth.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Among 8 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Adamas Pharmaceuticals had 20 analyst reports since August 7, 2015 according to SRatingsIntel. As per Thursday, May 12, the company rating was maintained by Mizuho. The firm earned “Buy” rating on Tuesday, August 15 by Mizuho. The rating was downgraded by Zacks to “Buy” on Friday, August 7. The firm earned “Market Outperform” rating on Friday, August 25 by JMP Securities. Credit Suisse maintained the shares of ADMS in report on Thursday, December 24 with “Outperform” rating. Mizuho maintained Adamas Pharmaceuticals Inc (NASDAQ:ADMS) rating on Tuesday, June 6. Mizuho has “Buy” rating and $2600 target. The firm has “Outperform” rating given on Tuesday, January 19 by Cowen & Co. The firm earned “Market Outperform” rating on Friday, April 1 by JMP Securities. The firm has “Buy” rating by Cowen & Co given on Wednesday, August 9. The company was maintained on Friday, August 25 by Mizuho.

More notable recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Fool.com which released: “Why Urban Outfitters, Pure Storage, and Adamas Pharmaceuticals Jumped Today” on August 25, 2017, also Seekingalpha.com with their article: “Adamas Prepares For Parkinson’s Launch” published on September 14, 2017, Seekingalpha.com published: “Cautious Optimism For Adamas Pharmaceuticals Going Into The ADS-5102 PDUFA Date” on August 22, 2017. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) were released by: Marketwatch.com and their article: “Adamas Pharma shares soar on Parkinson’s dyskinesia drug approval” published on August 24, 2017 as well as Marketwatch.com‘s news article titled: “Adamas Pharma says its new Parkinson’s drug isn’t just a more expensive, long …” with publication date: August 29, 2017.

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The company has market cap of $484.73 million. The Firm is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It currently has negative earnings. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.